Jane Huang, CMO, Hematology at BeiGene, Ltd. (BGNE), sold 1,500 shares at $376.16 ($572K) on 2021-11-17, disclosed to the SEC on 2021-11-19.
Seasonal sale ($572k) by CMO, Hematology — this insider has traded BGNE in November in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $376.16 | 200 | $75K | 13.2% |
| 2 | $377.14 | 300 | $113K | 19.8% |
| 3 | $377.92 | 100 | $38K | 6.6% |
| 4 | $379.88 | 100 | $38K | 6.6% |
| 5 | $381.41 | 200 | $76K | 13.3% |
| 6 | $382.42 | 100 |
| $38K |
| 6.7% |
| 7 | $384.16 | 100 | $38K | 6.7% |
| 8 | $385.28 | 100 | $39K | 6.7% |
| 9 | $387.94 | 300 | $116K | 20.3% |
| Total | $381.34 avg | 1,500 | $572K | 100% |
| Filing → |
| BGNE | SELL | 2021-12-02 | $755K | — | Filing → |
| BGNE | SELL | 2021-10-21 | $559K | — | Filing → |
| BGNE | SELL | 2021-09-22 | $3.6M | — | Filing → |